<DOC>
	<DOCNO>NCT02624557</DOCNO>
	<brief_summary>To characterize pharmacokinetics safety alpelisib subject hepatic impairment compare match healthy control subject .</brief_summary>
	<brief_title>Pharmacokinetic Study Alpelisib Subjects With Hepatic Impairment .</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Other hepatic impairment , subject good health determine past medical history , physical examination , vital sign , electrocardiogram ( except additional inclusion criterion hepatic impaired subject ) . Subjects must weigh least 50 kg 120 kg body mass index range 18.036.0 kg/m2 . Additional criterion hepatic impaired subject : Subjects must score clinically determine calculate per ChildPugh classification consistent degree hepatic impairment study currently enrol . Stable ChildPugh status within 28 day prior dose . All subject : Subject receive liver transplant time past immunosuppressant therapy . Smokers willing limit use tobacco 5 cigarette per day . Surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject 's safety case participation study . Use herbal medications/supplements . History acute pancreatitis within 1 year study entry . Additional criterion subject normal liver function : Use prescription nonprescription medication . Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Additional criterion hepatic impaired subject : Use prescription nonprescription medication , potential interact alpelisb . Concomitant medication without potential interact alpelisib must stable dose . Encephalopathy grade 3 worse . Total bilirubin &gt; 6 mg/dl . Screening baseline ECG : QTcF &gt; 480msec gender Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Clinical pharmacology study</keyword>
	<keyword>BYL719</keyword>
	<keyword>alpelisib</keyword>
</DOC>